Trial
NCT06388759
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
—
Condition
Myelofibrosis
Intervention
TQ05105 Tablets
Why stopped
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-29